See also this year's filing and all EDGAR filings for this company.
PDF Report 0001556263_2020_Syros_Pharmaceuticals_Inc.pdf
Logs
| warning | The stock price does not exist | industry.us_generic | {} |
| info | NetIncome node detected by revenue/expenses heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {'net_inc_node': 'OperatingIncomeLoss'} |
Graph
Absolute values for 0001556263, Syros Pharmaceuticals Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 114,513,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 15,210,000 |
| 3 | remainder_Assets | 20,255,000 |
| 4 | LiabilitiesCurrent | 23,516,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 25,600,259 |
| 9 | ResearchAndDevelopmentExpense | 59,875,020 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 1,984,183 |
| 12 | remainder_NetIncome | -687,887 |
| 13 | remainder_ComprehensiveNetIncome | 13,743,573 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 149,978,000 |
| 1 | Liabilities | 23,516,000 |
| 2 | Expenses | 85,475,279 |
| 3 | Revenues | 1,984,183 |
| 4 | StockholdersEquity | 126,462,000 |
| 5 | NetIncome | -84,178,983 |
| 6 | ComprehensiveNetIncome | -77,307,196 |
| 7 | BaseVar | 137,692,461 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 2.29 |
| 9 | EconomicCapitalRatio | 3.22 |
Edgar->Model Mapping
Feature Distribution
Change over Time
